Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 21, 2025; 31(11): 104033
Published online Mar 21, 2025. doi: 10.3748/wjg.v31.i11.104033
Published online Mar 21, 2025. doi: 10.3748/wjg.v31.i11.104033
Phospholipase D2: A biomarker for stratifying disease severity in acute pancreatitis?
Zhi-Hui Wang, Jia-Hui Lv, Ntim Michael, Yi-Fan Zhao, Min Xia, Bin Wang, Liaoning Provincial Key Laboratory of Cerebral Diseases, College of Basic Medical Sciences, National-Local Joint Engineering Research Center for Drug Research and Development of Neurodegenerative Diseases, Dalian Medical University, Dalian 116000, Liaoning Province, China
Yun Teng, The Second Affiliated Hospital, Dalian Medical University, Dalian 116000, Liaoning Province, China
Ntim Michael, Department of Physiology, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi 00233, Ashanti, Ghana
Min Xia, Department of Anesthesiology, General Hospital of The Yangtze River Shipping, Wuhan Brain Hospital, Wuhan 430012, Hubei Province, China
Co-first authors: Zhi-Hui Wang and Jia-Hui Lv.
Co-corresponding authors: Min Xia and Bin Wang.
Author contributions: Wang ZH and Lv JH contributed equally to this study as co-first authors; Xia M and Wang B contributed equally to this study as co-corresponding authors; Wang ZH and Lv JH contributed to the conceptualization and methodology of the study and drafted the original manuscript; Teng Y and Zhao YF conducted the formal analysis and contributed to the review and editing of the manuscript; Ntim M provided language review and polishing; Xia M and Wang B provided supervision and contributed to the review and editing of the manuscript; Wang B also acquired funding for the research.
Supported by National Natural Sciences Foundation of China, No. 82301700; Liaoning Province Natural Science Foundation Project, No. 2024-MS-157; Youth Talent Cultivation Fund Key Project of Dalian Medical University; Scientific Research Projects from Wuhan Municipal Health Commission, No. WX23Z26; and Science and Technology of Liaoning Province, No. 2023-MS-266.
Conflict-of-interest statement: The author reports no biomedical financial interests or potential conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin Wang, PhD, Professor, Liaoning Provincial Key Laboratory of Cerebral Diseases, College of Basic Medical Sciences, National-Local Joint Engineering Research Center for Drug Research and Development of Neurodegenerative Diseases, Dalian Medical University, No. 9 West Section, Lvshun South Road, Dalian 116000, Liaoning Province, China. wb101900@126.com
Received: December 8, 2024
Revised: February 3, 2025
Accepted: February 18, 2025
Published online: March 21, 2025
Processing time: 95 Days and 19.5 Hours
Revised: February 3, 2025
Accepted: February 18, 2025
Published online: March 21, 2025
Processing time: 95 Days and 19.5 Hours
Core Tip
Core Tip: The identification of reliable biomarkers for early stratification of disease severity is essential in the management of acute pancreatitis (AP). Phospholipase D2 (PLD2), a pivotal regulator of neutrophil migration and inflammatory responses, has emerged as a promising candidate biomarker that may transform AP management by integrating molecular diagnostics with precision medicine. However, several challenges persist, including large-scale validation studies, functional investigations to establish causation, and standardization of measurement protocols. Consequently, it is imperative to critically examine and rigorously validate the role of PLD2 to ensure its effectiveness in improving patient outcomes.